Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Advanced Non-small Cell Lung Cancer Clinical Trial

Official title:

Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03334864
• Other study ID #: JS-1410
• Status: Recruiting
• Start date: November 3, 2022
• Est. completion date: December 2025

Study information

• Verified date: November 2022
• Source: Peking Union Medical College Hospital
• Contact: Yan Xu, M.D.
• Phone: 861069155039
• Email: maraxu[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes.

Study type: Observational (Patient Registry)

Study design: Observational Model: Cohort

Time Perspective: Prospective and retrospective

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016;

• Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer;

• Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy;

• Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status;

• Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit;

• Age>18 years;

• Provision of written informed consent.

Exclusion Criteria:

• not applicable

Related Conditions & MeSH terms

• Advanced Non-small Cell Lung Cancer
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	OS was calculated from the diagnosis of advanced non-small cell lung cancer to death from any reasons	3 years